Drugs / Resminostat
Resminostat
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04955340 | Oct 2021 → Jan 2022 | Sezary syndrome, mycosis fungoides | 4SC AG | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02400788 | Apr 2013 → Jun 2016 | hepatocellular carcinoma | Yakult Honsha Co., LTD | Completed | No outcome recorded |
| Phase 1/2 | NCT01277406 | Jan 2011 → Feb 2013 | colorectal carcinoma | 4SC AG | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02953301 | Nov 2016 → Mar 2023 | Sezary syndrome, mycosis fungoides | 4SC AG | Completed | No outcome recorded |
| Phase 2 | NCT01037478 | Dec 2009 → Jan 2012 | Hodgkins lymphoma | 4SC AG | Completed | No outcome recorded |
| Phase 2 | NCT00943449 | Jul 2009 → Jun 2012 | hepatocellular carcinoma | 4SC AG | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resminostat | “4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma” NCT00943449 ↗ |
| Known as | 4SC-201 | “Resminostat (4SC-201)” NCT01037478 ↗ |
| Known as | BYK-408740 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4296717 ↗ |
| Known as | RAS-2410 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4296717 ↗ |
| Action | Inhibit | “HDAC Inhibitor” NCT01037478 ↗ |
| Modality | Small molecule | — CHEMBL4296717 ↗ |
| Route | Oral | “oral administration” NCT01037478 ↗ |